Kairos Pharma Ltd. (KAPA)
| Bid | 1.77 |
| Market Cap | 22.22M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.21 |
| PE Ratio (ttm) | -8.24 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.84 |
| Volume | 687,388 |
| Avg. Volume (20D) | 2,244,640 |
| Open | 1.85 |
| Previous Close | 1.77 |
| Day's Range | 1.69 - 2.08 |
| 52-Week Range | 0.85 - 4.00 |
| Beta | undefined |
About KAPA
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, Califo...
Analyst Forecast
According to 2 analyst ratings, the average rating for KAPA stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 420.23% from the latest price.
3 weeks ago · seekingalpha.com
Kairos Pharma: Potential To Remove Resistance With Established DrugsENV-105 targets CD105 proteins to restore sensitivity in cancer cells, enhancing the efficacy of existing therapies like ERLEADA and TAGRISSO. Kairos Pharma's ENV-105 aims to overcome resistance in CR...
